Fuji Co., Ltd.
(Progress on Disclosure Matters) Notice Regarding Transfer of Shares in Equity-Method Affiliate and Recognition of Extraordinary Income
Fuji Corporation has transferred all shares of its equity-method affiliate Lady Pharmacy Co., Ltd., and expects to record extraordinary income of ¥8,189 million from sale of investment securities in the consolidated financial results for the fourth quarter of fiscal 2026 ending February, as well as extraordinary income of ¥17,447 million from sale of equity-method affiliate shares in its non-consolidated financial results.
Key Figures
- Gain on Sales of Investment Securities (Extraordinary Income): ¥8,189 million (expected in consolidated financial results for fourth quarter of fiscal 2026 ending February)
- Gain on Sales of Equity-Method Affiliate Shares (Extraordinary Income): ¥17,447 million (expected in non-consolidated financial results for fiscal 2026 ending February)
- Share Transfer Date: 2025-11-20 (disclosed)
AI要約
Overview of Transfer of Equity-Method Affiliate Shares
Fuji Corporation has transferred all shares held in its equity-method affiliate Lady Pharmacy Co., Ltd. As a result, an extraordinary gain of ¥8,189 million from the sale of investment securities is expected to be recorded in the consolidated financial results for the fourth quarter of fiscal 2026 ending February, and an extraordinary gain of ¥17,447 million from the sale of equity-method affiliate shares is expected in the non-consolidated financial results.
Impact on Earnings Guidance
The recognition of this extraordinary income from the share transfer has already been reflected in the consolidated earnings guidance disclosed in the financial summary for the third quarter of fiscal 2026 ending February. The impact of the transfer has been incorporated into the earnings forecast, and the effect on future earnings is expected to be limited.
